Pharmaceutical

Sienna Biopharmaceuticals (NASDAQ:SNNA) reported the Company’s financial results for the fourth quarter and full year of 2017. As quoted in the press release: “We are pleased to report the results of our fourth quarter and first year ended as a public company,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. …

Sienna Biopharmaceuticals (NASDAQ:SNNA) reported the Company’s financial results for the fourth quarter and full year of 2017.

As quoted in the press release:

“We are pleased to report the results of our fourth quarter and first year ended as a public company,” said Frederick C. Beddingfield III, M.D., Ph.D., President and Chief Executive Officer of Sienna. “We continue to execute across our innovative multi-asset pipeline. We are well under way with our Phase 2b trial of SNA-120 and recently entered the clinic with two separate proof-of-concept trials of SNA-125. These product candidates from our Topical by Design™ platform have the potential to address very large patient populations in atopic dermatitis, psoriasis and pruritus. We are eager for data readouts from our five clinical programs, beginning in the second half of this year, and believe there is additional potential in our Topical by Design™ and Topical Photoparticle Therapy™ platforms.”

Click here to read the full press release.

Featured

MARKETS

Markets
TSX19890.06-109.63
TSXV711.19-8.62
DOW32160.74-84.96
S&P 5004001.05+9.81
NASD11737.67+114.42
ASX7051.20-69.50

COMMODITIES

Commodities
Gold1849.39+16.02
Silver21.66+0.40
Copper4.21+0.05
Palladium2066.50+29.50
Platinum987.00+24.00
Oil101.81+2.05
Heating Oil3.73+0.05
Natural Gas7.48+0.09

DOWNLOAD FREE REPORTS

×